The two main aims of this clinical study is;
1. To investigate if the results from a series of physiological tests and questionnaires prior to treatment, can be used to predict the treatment response to obesity medication
2. To investigate the effect of combining semaglutide and pramlintide on various aspects of appetite, food preference and eating habits.
The study is planed as a 26 week, double blinded, randomized, placebo controlled trial. The goal is to include N=40. They will all receive weekly semaglutide injections. After 24 weeks they will be randomized to receive either an amylin analog (pramlintide) or placebo as a continuous infusion for two weeks, in addition to weekly semaglutide.
The results from this study will contribute to identifying possible predictors of treatment response, enabling optimal individualized medical weight loss treatment. As well as providing knowledge on the complex interplay between incretin hormones and their effects on appetite and eating habits.

Start Date01 Apr 2025

Sponsor / Collaborator-

NCT06186063

/ Unknown statusNot ApplicableIIT

The Role of Amylin in Bone Metabolism

The clinical study aims to investigate the effect of the intravenously administrated amylin analogue (pramlintide) on the circulating levels of C-terminal telopeptide of type I collagen (CTX-1) (a marker of bone resorption) and N-terminal propeptide of type I procollagen (P1NP) (a marker of bone formation) in individuals with type 1 diabetes and matched healthy controls during fasting euglycemic conditions.

Start Date12 Feb 2024

Sponsor / Collaborator-

NCT05199714

/ CompletedNot ApplicableIIT

A Randomized, Controlled, Crossover Pilot Trial to Assess a Fully Automated, Dual-hormone (Insulin-and-pramlintide) Artificial Pancreas Without Carbohydrate Counting in Regulating Glucose Levels in Adults With Type 1 Diabetes

The investigators aim to assess the glycemic outcomes of a fully automated insulin-and-pramlintide artificial pancreas and a comparator insulin-alone artificial pancreas with carbohydrate matched boluses.

Start Date21 Feb 2022

Sponsor / Collaborator

Centre universitaire de santé McGill

[+1]

100 Clinical Results associated with Pramlintide Acetate

100 Translational Medicine associated with Pramlintide Acetate

100 Patents (Medical) associated with Pramlintide Acetate

407

Literatures (Medical) associated with Pramlintide Acetate

01 Sep 2026·DIABETES OBESITY & METABOLISM

Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early‐Phase Clinical Trials

Review

Author: le Roux, Carel W. ; Alhazmi, Abdulhameed

ABSTRACT:

Aims:

The management of the disease of obesity has been transformed by incretin‐based therapies; however, additional and alternative therapeutic strategies are needed to address its biological complexity. This narrative review examines the physiology of amylin and the emerging role of amylin‐based therapies in obesity management.

Materials and Methods:

We conducted a narrative review of amylin‐based therapies that were approved or remained in human clinical development for obesity as of 30 April 2026. PubMed/MEDLINE, ClinicalTrials.gov, Google Scholar, company press releases, investor reports, and major congress abstracts were searched for relevant preclinical and clinical evidence.

Results:

Amylin, co‐secreted with insulin from pancreatic β‐cells, slows gastric emptying, suppresses glucagon secretion, and promotes meal termination through central mechanisms. Pramlintide, the first approved amylin analogue, established proof of concept but was limited by modest efficacy and frequent dosing. More recently, long‐acting amylin‐based therapies, including cagrilintide, eloralintide, petrelintide, MET‐233i, ABBV‐295, and AZD6234, as well as combination approaches such as cagrilintide with semaglutide and zenagamtide, have demonstrated clinically meaningful weight loss with generally favorable tolerability profiles.

Conclusions:

Amylin‐based therapies represent a promising addition to the evolving treatment landscape of obesity. Their emerging efficacy as both standalone and combination therapies supports a multi pathway approach to addressing the biological complexity and heterogeneity of the disease.

01 Jul 2026·JOURNAL OF INORGANIC BIOCHEMISTRY

Metal-tuned antimicrobial peptides and zincophore pathways: from coordination chemistry to targeted therapeutics

Review

Author: Rowińska-Żyrek, Magdalena ; Garstka-Litwin, Kinga

Escalating resistance among bacterial and fungal pathogens calls for new therapeutic strategies that go beyond classical small-molecule antibiotics. Antimicrobial peptides (AMPs) are attractive candidates because they can act through multiple mechanisms and often evade conventional resistance pathways. Biologically essential metal ions such as Zn(II) and Cu(II) further expand this chemical space: metal binding can modulate peptide structure, morphology, local charge and transport, thereby generating metallo-AMPs with distinct modes of action. In this review, we discuss selected Zn(II)- and Cu(II)-binding AMPs and peptidic zincophores in which the link between coordination chemistry and biological activity has been analysed in detail. Rather than simply listing examples, we use these systems to show how a coherent research programme in bioinorganic AMP chemistry can be built around one guiding idea: connecting metal coordination to function across different peptide families. Pramlintide and shepherins illustrate Zn(II)-driven conformational change and fibril formation associated with antifungal activity. Semenogelins and calcitermin highlight how histidine-rich motifs and local charge tuning can activate peptides without relying on nutritional immunity. Clavanins reveal a "chemical butterfly effect", where subtle differences in pre-organization translate into changes in complex lability and antimicrobial outcome. Histatin systems show that metal-dependent effects can be strongly pH-gated. Finally, thermodynamic and structural studies of fungal zincophores and bacterial periplasmic transporters provide a basis for targeted peptide designs that exploit Zn(II) uptake pathways. Together, these case studies outline mechanism-based design principles for future metal-peptide therapeutics.

01 Jun 2026·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

In vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in the context of preventive doping research

Article

Author: Alhalabi, Hana ; Thomas, Andreas ; Le Foll, Christelle ; Bally, Lia ; Borschel, Lisa ; Thevis, Mario

Peptide hormone-based weight-loss therapeutics have gained increasing attention, driven amongst other reasons, by the clinical and commercial success of semaglutide. Their increasing accessibility raises concerns about their potential misuse in sports, especially in disciplines where weight management is decisive for athletic performance. Semaglutide has been included in the World Anti-Doping Agency's monitoring program since 2024. Given that amylin signalling is a key therapeutic target for next-generation weight-loss drugs, amylin receptor agonists such as pramlintide, cagrilintide and KBP-066 also warrant consideration as to metabolism and detection strategies in sports drug testing programs. This study aimed to characterize the metabolic profiles of pramlintide, cagrilintide and KBP-066, identify analytically suitable metabolites and develop and validate a LC-MS/MS-based detection approach. Comprehensive in vitro models, including human skin S9 fraction, kidney S9 fraction and biological fluids, were used to investigate metabolic pathways. HRMS/MS was employed to characterize metabolites and evaluate their suitability as analytical targets. For comparison, authentic post-administration rat samples were analysed for cagrilintide and respective biotransformation products. All three peptides underwent N-terminal and C-terminal degradation, yielding multiple stable metabolic products suitable as detection targets. Cagrilintide metabolites predicted from in vitro experiments were observed in authentic post administration rat plasma samples, confirming in vivo relevance. Finally, suitable preparation and detection methods were established and validated. This study provides the first systematic metabolic characterization of pramlintide, cagrilintide and KBP-066. The identified metabolites and LC-MS/MS detection approach offer a foundation for future monitoring of emerging weight-loss peptide hormone analogues in anti-doping contexts.

News (Medical) associated with Pramlintide Acetate

30 Jul 2026

·www.biospace.com

Meitheal Pharmaceuticals Announces FDA Approval of Garzulys™ (insulin aspart-fsan) Injection

FDA approves Garzulys™ (insulin aspart-fsan), a rapid-acting insulin analog to improve glycemic control in adults and pediatric patients with diabetes mellitus Meitheal serves as the U.S. Regulatory Agent for Garzulys and holds exclusive U.S. commercialization rights under its license agreement with Emerge, the BLA holder Approval marks an important milestone in Meitheal’s continued expansion into complex biologics and essential medicines CHICAGO--(BUSINESS WIRE)--Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated biopharmaceutical company headquartered in Chicago and focused on the development and commercialization of generic injectable medicines, biologics, fertility products and branded medicines, today announced that the U.S. Food and Drug Administration (“FDA”) has approved Garzulys™ (insulin aspart-fsan) injection, a biosimilar to NovoLog ® (insulin aspart). Emerge Bioscience Pte. Ltd. (“Emerge”) is the holder of the approved Biologics License Application (BLA) for Garzulys. Meitheal serves as the product’s U.S. Regulatory Agent and holds exclusive U.S. commercialization rights under its license agreement with Emerge. Garzulys is a rapid-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. Garzulys formulations are approved for both subcutaneous and intravenous administration. Please see the Important Safety Information below. Garzulys was developed through a collaboration between Tonghua Dongbao Pharmaceutical Co., Ltd. (“Tonghua Dongbao”) and companies affiliated with Meitheal. Tonghua Dongbao was responsible for drug substance development, Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (“NKF”) was responsible for drug product development, Xentria, Inc. (“Xentria”) led the clinical development program, and Meitheal, serving as the U.S. Regulatory Agent, led the U.S. regulatory work supporting FDA approval. Emerge is the BLA holder and is responsible for key supply-chain activities associated with the product. ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); The collaboration initiated in 2023 between Tonghua Dongbao and NKF encompasses Garzulys and two additional insulin biosimilar candidates currently in development. Through its exclusive license agreement with Emerge, Meitheal holds exclusive U.S. commercialization rights for Garzulys and the two additional product candidates. “The FDA approval of Garzulys represents an important milestone in Meitheal’s continued expansion beyond our established generic injectable business and into a broader portfolio of biologics and branded products,” said Tom Shea, Chief Executive Officer of Meitheal. “We are making deliberate, long-term investments in the regulatory expertise, commercial infrastructure and strategic partnerships needed to expand patient access to high-quality biologic treatment options. Our leadership of the U.S. regulatory process for Garzulys demonstrates the strength of our platform and the disciplined execution we bring to complex products and global partnerships.” This approval further expands Meitheal’s presence in diabetes care and advances the company’s strategy to build a broader portfolio of biologics and branded products. Since its founding in 2017, Meitheal has developed a diversified U.S. platform supporting more than 80 FDA-approved products across therapeutic areas including anti-infectives, oncology, anesthesia, diabetes, critical care and fertility. INDICATIONS AND USAGE Garzulys™ (insulin aspart-fsan) injection is a rapid acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. IMPORTANT SAFETY INFORMATION FOR GARZULYS™ Garzulys (insulin aspart-fsan) is biosimilar* to NovoLog (insulin aspart). Contraindications Garzulys™ is contraindicated during episodes of hypoglycemia and in patients hypersensitive to Garzulys or one of its excipients. Warnings and Precautions Never Share a Garzulys Prefilled Pen between Patients, even if the needle is changed. Patients using Garzulys vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens. Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Changes in an insulin regimen (e.g., insulin strength, manufacturer, type, or injection site or method of administration) may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis have been reported to result in hyperglycemia; and a sudden change in the injection site (to an unaffected area) has been reported to result in hypoglycemia. Make any changes to a patient’s insulin regimen under close medical supervision with increased frequency of blood glucose monitoring. Advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor for hypoglycemia. For patients with type 2 diabetes, dosage adjustments of concomitant anti-diabetic products may be needed. Hypoglycemia: Hypoglycemia is the most common adverse effect of all insulins, including insulin aspart products. Severe hypoglycemia can cause seizures, may lead to unconsciousness, may be life threatening or cause death. Hypoglycemia can impair concentration ability and reaction time; this may place an individual and others at risk in situations where these abilities are important (e.g., driving or operating other machinery). Hypoglycemia can happen suddenly and symptoms may differ in each individual and change over time in the same individual. Symptomatic awareness of hypoglycemia may be less pronounced in patients with longstanding diabetes in patients with diabetic nerve disease, in patients using medications that block the sympathetic nervous system (e.g., beta-blockers), or in patients who experience recurrent hypoglycemia. Risk Factors for Hypoglycemia: The risk of hypoglycemia after an injection is related to the duration of action of the insulin and, in general, is highest when the glucose lowering effect of the insulin is maximal. As with all insulins, the glucose lowering effect time course of Garzulys may vary in different individuals or at different times in the same individual and depends on many conditions, including the area of injection as well as the injection site blood supply and temperature. Other factors which may increase the risk of hypoglycemia include changes in meal pattern, changes in level of physical activity, or changes to concomitantly administered medication. Patients with renal or hepatic impairment may be at higher risk of hypoglycemia. Patients and caregivers must be educated to recognize and manage hypoglycemia. Hypoglycemia Due to Medication Errors: To avoid medication errors and accidental mix-ups between Garzulys and other insulin products, instruct patients to always check the insulin label before injection. Hypersensitivity Reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, may occur with insulin products, including Garzulys. Hypokalemia: All insulins, including Garzulys, can cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia if indicated (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentration). Fluid Retention and Heart Failure with Concomitant Use of PPAR-gamma Agonists: Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs), which are PPAR-gamma agonists, and insulin, including Garzulys. Patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of the TZD must be considered. Hyperglycemia and Ketoacidosis Due to Insulin Pump Device Malfunction: Malfunction of the insulin pump or insulin infusion set or insulin degradation can rapidly lead to hyperglycemia and ketoacidosis. Prompt identification and correction of the cause of hyperglycemia or ketosis is necessary. Patients using insulin infusion pump therapy must be trained to administer insulin by injection and have alternate insulin therapy available in case of pump failure. Garzulys continuous subcutaneous infusion route (insulin pump): Do not mix Garzulys with any other insulin or diluent. Adverse Reactions Adverse reactions observed with Garzulys include hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus. Drug Interactions Drugs that may increase the risk of hypoglycemia: antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics. Drugs that may decrease the blood glucose lowering effect: atypical antipsychotics, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. Drugs that may increase or decrease the blood glucose lowering effect: alcohol, beta-blockers, clonidine, lithium salts, and pentamidine. Drugs that may blunt the signs and symptoms of hypoglycemia: beta-blockers, clonidine, guanethidine, and reserpine. *Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of Garzulys has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. Please see Prescribing Information for Garzulys Additional Patient Information Leaflets are available at or call 1-844-824-8426. ABOUT MEITHEAL PHARMACEUTICALS, INC. Founded in 2017 and headquartered in Chicago, Meitheal Pharmaceuticals, Inc. is a fully integrated biopharmaceutical company focused on the development and commercialization of generic injectable, biologic, fertility and branded products. Meitheal currently markets more than 80 FDA-approved products across therapeutic areas including anti-infectives, oncology, anesthesia, diabetes, critical care and fertility. Meitheal combines an established U.S. commercial platform with regulatory expertise and strategic development and manufacturing partnerships to support complex pharmaceutical products. Building on its foundation in generic injectables, the company is making deliberate, long-term investments to expand its biologics and branded portfolio and broaden access to high-quality, fairly priced medicines. Meitheal is guided by the traditional Irish principle for which it is named—working together toward a common goal, for the greater good. Learn more at . ABOUT TONGHUA DONGBAO PHARMACEUTICAL CO., LTD. Founded in 1985 and based in Jilin Province, China, Tonghua Dongbao Pharmaceutical Co., Ltd. (“Tonghua Dongbao”) is a biopharmaceutical company specializing in the research, development, manufacturing and commercialization of therapies for diabetes and other endocrine and metabolic diseases. In 1998, Tonghua Dongbao developed China’s first domestically produced recombinant human insulin. The company’s portfolio and pipeline include human insulin, insulin analogs, GLP-1 receptor agonists and other therapies for diabetes and related metabolic conditions. Tonghua Dongbao is publicly listed on the Shanghai Stock Exchange under stock code 600867. ABOUT EMERGE BIOSCIENCE PTE. LTD. Established in 2024 and based in Singapore, Emerge Bioscience Pte. Ltd. (“Emerge”) is a subsidiary of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (“NKF”) that supports NKF’s international pharmaceutical trading and supply-chain activities. Emerge coordinates with manufacturers, regulatory authorities, logistics providers and commercial partners to support the reliable, compliant and timely delivery of pharmaceutical products and NKF’s broader international growth strategy. ABOUT NANJING KING-FRIEND BIOCHECMICAL PHARMACEUTICAL CO., LTD. Founded in 1986 and headquartered in Nanjing, China, Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (“NKF”) is an integrated biopharmaceutical company engaged in the research, development and manufacturing of active pharmaceutical ingredients and finished dosage forms. Building on its established expertise in heparin APIs and sterile injectable products, NKF has expanded its capabilities across generic, biologic and branded products in therapeutic areas including oncology, critical care, fertility and diabetes. NKF supports products and partners in the United States, China, Europe and other global markets and is publicly listed on the Shanghai Stock Exchange under stock code 603707. ABOUT XENTRIA, INC. Established in 2020, Xentria Inc. (“Xentria”) works across life science communities creating innovative and authentic collaborations and partnerships that advance challenging drug development. Xentria, derived from “centrality”, is dedicated to delivering customized approaches to ambitious drug innovation through meaningful patient engagement and effective partnerships. Headquartered in Chicago, Xentria is taking the lead to support surging life sciences initiatives for global audiences, while nurturing diversity, individualism, and sustainability. To learn more about Xentria visit MAT-US-BIO-00002-1 07/2026 Contacts MEDIA CONTACT Meitheal Pharmaceuticals, Inc. John Spilman, VP of Corporate Strategy 773 899 5910 info@meithealpharma.com

License out/inDrug Approval

05 Mar 2025

·www.echemi.com

AbbVie Invests $2.2 Billion to Develop Best-in-Class Obesity Drug

On March 3, 2025, AbbVie and Gubra announced a significant licensing agreement to collaboratively develop GUB014295, a promising long-acting amylin analogue aimed at treating obesity. This partnership marks AbbVie’s strategic entry into the obesity treatment market. As part of the agreement, AbbVie will oversee the global development and commercialization of GUB014295. Gubra is set to receive an upfront payment of $350 million and could earn up to $1.875 billion in milestone payments related to development, commercialization, and sales, along with tiered royalties on global net sales. Currently, GUB014295 is undergoing Phase I clinical trials. This innovative drug specifically activates amylin and calcitonin receptors, helping regulate appetite and promote satiety. Initial results from a single ascending dose trial indicated that GUB014295 was well-tolerated, with mild and transient gastrointestinal side effects. The drug exhibited favorable pharmacokinetic properties, with a half-life of 11 days, supporting weekly dosing. During the six-week trial, patients in the high-dose group (3.5 - 6.0 mg) experienced an average weight loss of about 3%, while those on placebo saw an increase of approximately 1%. A multiple ascending dose trial is currently underway, with mid-term results expected in the first half of 2025. Amylin, a 37-amino acid hormone, plays a critical role in glucose control and appetite regulation. Its potential as a therapeutic target for obesity is underscored by existing amylin analogues like Symlin, which has been on the market since 2005 for diabetes management. AbbVie’s investment in GUB014295 highlights the growing interest in effective obesity treatments, reflecting a broader trend in the pharmaceutical industry to address the rising global obesity epidemic. With this collaboration, AbbVie aims to leverage Gubra's innovation in the hope of bringing a groundbreaking obesity therapy to market.

Phase 1License out/inClinical Result

10 Jan 2025

·www.prnewswire.com

Iktos and Cube Biotech Announce Launch of Small Molecule AI Drug Discovery Collaboration

Partnership will leverage Iktos's AI-enabled drug discovery platform and Cube Biotech's advanced protein technologies to develop novel agonists of the Amylin Receptor PARIS and MONHEIM, Germany, Jan. 10, 2025 /PRNewswire/ -- Iktos, a leader in Artificial Intelligence (AI) and Robotics for drug design, and Cube Biotech, a pioneer in membrane protein production and purification technologies, today announced a strategic collaboration to discover novel small molecule agonists of the Amylin Receptor. The partnership combines Iktos' generative AI-driven drug discovery and robotic synthesis platform with Cube Biotech's advanced native membrane protein technology NativeMPTM, as well as their purification and biophysical assay expertise, to accelerate the development of breakthrough therapies. This paves the way for a joint collaborative offering directed towards pharmaceutical companies, combining the strengths of both platforms to undertake their most challenging drug discovery programs. Amylin receptor agonists hold significant promise for addressing unmet medical needs in cardiometabolic disorders, including obesity, diabetes, and metabolic dysfunction-associated steatotic hepatitis (MASH). The Amylin Receptor regulates appetite and satiety, making it a compelling target for obesity, which affects over one-third of the global population. Existing GLP-1 receptor agonist therapies like semaglutide or the peptide Amylin analogue Pramlintide have limited impact due to high costs, accessibility, and undesirable side effects. Orally administered novel small molecule agonists of the Amylin receptor could overcome these barriers, offering scalable and effective treatments and providing better management for the growing obesity epidemic and its comorbidities. However, the receptor's structural and biological complexity has long posed challenges for discovering viable low-molecular-weight modulators. "By tackling one of the most pressing unmet needs in cardiometabolic disorders, our partnership with Cube Biotech aims to discover improved treatments for patients affected by obesity, diabetes, and related conditions," said Yann Gaston-Mathé, Co-founder and CEO of Iktos. "We are excited to add the Amylin Receptor to our pipeline as this complex, yet promising target demands innovation at every stage. We see this collaboration as a foundation for future initiatives, extending the reach of our combined platform to address the most challenging membrane targets for the benefit of our pharma partners." Iktos has developed a cutting-edge 3D generative chemistry technology for structure-guided de novo design that natively accounts for protein flexibility during molecule optimization—a key advantage over models like AlphaFold, which can only be applied post-molecule generation. Cube Biotech has developed a world-leading protein production platform, based on NativeMP™ technology, which preserves the natural configuration of membrane proteins - a key advantage in accessing biologically active drug targets for testing. The company's native protein stabilization technology enhances the reliability and precision of functional assays, structural insights, and downstream applications. "Amylin Receptor is a challenging but highly promising target for metabolic disorders", said Dr. Barbara Maertens, Co-founder and COO of Cube Biotech. "Through our collaboration with Iktos, we aim to leverage our advanced protein stabilization and structural analysis technologies to validate and accelerate the discovery of novel small molecule agonists. Together, we are setting a new standard for efficiency and innovation in drug discovery." These integrated technologies endeavor to overcome longstanding inefficiencies in drug discovery, shortening timelines, improving success rates, and unlocking new possibilities for targeting complex and historically elusive membrane proteins, such as G-protein coupled receptors (GPCRs), membrane transporters, ion channels, and others. About Iktos Iktos is a leader in artificial intelligence and robotic solutions applied to research in medicinal chemistry and new drug design. Iktos' proprietary and innovative generative AI solution enables the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology through the SaaS software platforms Makya™ for generative drug design and Spaya™ for retrosynthesis, and through strategic collaborations with pharma companies where Iktos mobilizes its unique platform and leading-edge capabilities to expedite small molecule drug discovery for the benefit of its partners. Iktos has also developed Iktos Robotics, a unique AI-driven synthesis automation platform that dramatically accelerates the Design-Make-Test-Analyze cycle in drug discovery and is developing its own pipeline of drug candidates targeting oncology and auto-immune and inflammatory diseases. In March 2023, Iktos completed a 15.5M€ Series A financing round co-led by M Ventures and Debiopharm Innovation with contribution by Omnes Capital. In July 2024, Iktos announced the acquisition of Synsight, thereby complementing its Chemistry AI platform with a groundbreaking biology platform for the discovery of new drugs targeting Protein-Protein Interactions (PPI) and RNA-Protein Interactions (RPI). About Cube Biotech Cube Biotech is a leader in membrane protein production, purification, and characterization technologies. With proprietary copolymer-based solutions that maintain biological integrity in native-like protein states, Cube Biotech enables groundbreaking research in challenging drug targets, including membrane receptors, protein co-expressions, and even larger complexes. The company's expertise in assay development, biophysical characterization, and structural resolution supports efficient drug discovery workflows across the pharmaceutical and biotechnical industries. Additionally, an extensive purification resin and magnetic bead portfolio for affinity chromatography and efficient protein purification is manufactured in-house at high quality. For more information, visit . Media Contact: Eleonora Echegaray P: 35 823189279 E: [email protected] SOURCE Iktos WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Acquisition

100 Deals associated with Pramlintide Acetate

External Link

KEGG	Wiki	ATC	Drug Bank
D05595	Pramlintide Acetate	A10BX05	DB01278

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 1	United States	AstraZeneca AB	16 Mar 2005
Diabetes Mellitus, Type 2	United States	AstraZeneca AB	16 Mar 2005

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Obesity, Abdominal	Phase 2	United States	AstraZeneca PLC	01 Oct 2006
Obesity	Phase 2	United States	AstraZeneca PLC	01 Aug 2004

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01841359 (CTgov)	Phase 4	Hypoglycemia \| Stomach Diseases	22	Pramlintide (Baseline (Prior to Pramlintide Treatment) Mixed Meal #1)	gjcfcgcocu(dilrbiowqt) = psypvcxyhh pwamedrwfc (mtqjjiaaxj, 3255) View more	-	26 May 2022
				Pramlintide (Pramlintide - Mixed Meal #2)	gjcfcgcocu(dilrbiowqt) = dzjmpianrg pwamedrwfc (mtqjjiaaxj, 2770) View more
ENDO2021	Phase 2	Diabetes Mellitus, Type 1	18	XP-3924	kwethulxfw(ictndyclig) = The incidence and severity of treatment emergent adverse events (e.g., injection site reactions, minimal nausea and vomiting) was comparable across all treatment arms with no drug-related serious adverse events eoliybjnhg (vqevnohzdq )	Positive	03 May 2021
				Regular Insulin (Humulin R) + Pramlintide (Symlin)
NCT00690235 (CTgov)	Phase 4	Diabetes Mellitus \| Schizoaffective disorder \| Schizophrenia ... View more	33	Pramlintide (Pramlintide)	fmximqolja(wjgjpsnxbt) = gaecxtadhv hmqjugxkbd (mazjrfymgt, 143.06) View more	-	16 Nov 2018
				Placebo (Placebo)	fmximqolja(wjgjpsnxbt) = oucxjmvdkv hmqjugxkbd (mazjrfymgt, 109.26) View more
NCT02500979 (CTgov)	Phase 1	Diabetes Mellitus, Type 1	34	Insulin (Placebo & Regular Insulin)	nuqurgijio(nxpzsxjcfp) = dqosjrrqqq ryogimjucm (kygsculplm, 8.17) View more	-	02 Nov 2018
				Insulin+Pramlintide (Pramlintide & Regular Insulin)	nuqurgijio(nxpzsxjcfp) = tsnrzofwgi ryogimjucm (kygsculplm, 8.17) View more
NCT02500979 (Pubmed \| Diabetes Care)	Phase 1	Diabetes Mellitus, Type 1	34	Pramlintide	yjposkhzzv(rbeicuzhyq) = rdkhrdtror sazidsbvrs (yrpnxdgclq )	-	01 Nov 2018
				Placebo	yjposkhzzv(rbeicuzhyq) = oczqblqsrr sazidsbvrs (yrpnxdgclq )
NCT00442767 (CTgov)	Phase 4	Diabetes Mellitus, Type 1 \| Hyperglycemia	8	Insulin (Rapid Acting Insulin Therapy - Before Meal)	esijgrmphp(ethtldxbke) = rlsojnmlpz svrqadjkoi (snnbibfirs, 116) View more	-	10 Jul 2018
				Insulin+Pramlintide (Pre-meal Pramlintide and Post-meal Insulin Therapy)	esijgrmphp(ethtldxbke) = koalxcgwgw svrqadjkoi (snnbibfirs, 141) View more
NCT01269047 (CTgov)	Phase 4	Diabetes Mellitus, Type 1 \| Hyperglycemia	37	Insulin (Insulin Monotherapy)	cigcxzvhxw(eghaceopwm) = gfpvsookzl voxqulbpxh (umljzvjwhg, 3.8) View more	-	08 Feb 2018
				Pramlintide (Pramlintide + Insulin Group)	ulaclqfjyi(vzjmepdsmo) = cmzhdmpgul ufzojylcse (vpbkbbysso, nzyvdsmskh - jkrjrraffy) View more
NCT00392925 (CTgov)	Phase 2	Obesity, Abdominal \| Obesity	177	Metreleptin (Metreleptin)	qearcxhobr(hlneybdxmj) = nbmnlhrwgu oqenaowtry (nwidgjveqj, 0.952) View more	-	28 Feb 2014
				Pramlintide Acetate (Pramlintide Acetate)	qearcxhobr(hlneybdxmj) = fatfxbwwtn oqenaowtry (nwidgjveqj, 0.698) View more
NCT00673387 (CTgov)	Phase 2	Obesity	636	pramlintide acetate+metreleptin (Pramlintide 180 mcg + Metreleptin 2.5 mg)	iiymvryszq(wqcdzeaylg) = gomxscfiem ecesgictve (dmupdvhail, flrfqnvzyp - hgjxpvvhss) View more	-	14 Nov 2013
				pramlintide acetate+metreleptin (Pramlintide 180 mcg + Metreleptin 5.0 mg)	iiymvryszq(wqcdzeaylg) = cvgjhiheec ecesgictve (dmupdvhail, bxrqhpptsj - jqcsvdwwqz) View more
NCT00108004 \| NCT00042458 (Pubmed \| Postgrad Med) Manual	Phase 3	Diabetes Mellitus, Type 1	305	Pramlintide (RCT)	cdnleojplc(jujeqawsmo) = Short-lived nausea, primarily mild to moderate in intensity, was the most common adverse event associated with pramlintide therapy fyywbxyzhu (jzkomzjqlq ) View more	Positive	01 May 2013
				Placebo (RCT)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis